Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Published version of a preprint
The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
Immunotherapy has recently entered a renaissance phase with the approval of multiple agents for the treatment of cancer. Immunotherapy stands ready to join traditional modalities, including surgery, chemotherapy, radiation, and hormone therapy, as a pillar of cancer treatment. Although immunotherapy has begun to have success in advanced cancer treatment, its scheduling and efficacy with surgery to treat earlier stages of cancer and prevent distant metastases have not been systematically examined. Here, we have used two models of spontaneously metastatic breast cancers in mice to illustrate the significantly greater therapeutic power of neoadjuvant, compared with adjuvant, immunotherapies in the context of primary tumor resection. Elevated and sustained peripheral tumor-specific immune responses underpinned the outcome, and blood sampling of tumor-specific CD8+ T cells immediately prior to and post surgery may provide a predictor of outcome. These data now provide a strong rationale to extensively test and compare neoadjuvant immunotherapy in humans. Significance: We demonstrate the significantly greater therapeutic efficacy of neoadjuvant, compared with adjuvant, immunotherapies to eradicate distant metastases following primary tumor resection. Elevated and sustained peripheral tumor-specific immune responses underpinned the outcome, and blood sampling of tumor-specific CD8+ T cells immediately prior to and post surgery may provide a predictor of outcome. Cancer Discov; 6(12); 1382–99. ©2016 AACR. See related commentary by Melero et al., p. 1312. This article is highlighted in the In This Issue feature, p. 1293
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Data from a landmark study using an orthotopic model of breast cancer showed that neoadjuvant ICIs might outperform adjuvant ICIs106.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [106]
In the citing paper
“Delivering ICIs after surgery enabled T cell expansion, and yielded the best antitumour activity while also decreasing toxicity106.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [106]
Citations
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Cited by
Items 801–900 of 930
Emerging Immunotherapy: Liver Cancer Microenvironment for Treatment
Liu, S. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.106021
Update on immune checkpoint therapy for melanoma
Everdell, E., & Tsao, H. (2022) · Dermatological Reviews · doi:10.1002/der2.164
Morgensztern, D., Boffa, D. J., Chen, A. J., Dhanasopon, A. P., Goldberg, S. B., Decker, R. H., Devarakonda, S. H. K., Ko, J. P., Soto, L. M. S., Waqar, S. N., et al. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm085.pub2 · Cited by 1
Meng, J., Tan, T. J., Ye, J., Goh, D. L. M., Lim, C. J., Koh, V. C. Y., Wee, F. Y. T., Lim, J. C. T., Joseph, C. R., Tay, T. K. Y., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-sitc2022.1039
(2022) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-022-00861-2
Neo-Adjuvant Therapies in Lung Cancer – Past Present and Future Directions
(2022) · European Journal of Respiratory Medicine · doi:10.31488/ejrm.131
IFNγ score–based neoadjuvant immunotherapy for stage III melanoma
Fukuda, K. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20230160
Immune Checkpoint Inhibitors in the Curative Setting: Pre-clinical and Clinical Data
Beyaert, S. P., Honoré, N., & Machiels, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-23175-9_11
Hong, W. X., Sagiv-Barfi, I., Czerwinski, D. K., Sallets, A., & Levy, R. (2023) · doi:10.1158/0008-5472.c.6513799.v1
Hong, W. X., Sagiv-Barfi, I., Czerwinski, D. K., Sallets, A., & Levy, R. (2023) · doi:10.1158/0008-5472.c.6513799
Research Hotspot and Application Status of Immune Evasion Mechanism in Ovarian Cancer
Zhang, Y., & Wang, H. (2023) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2023.114032
Research progress on immune checkpoint inhibitors in neoadjuvant therapy for gastric cancer
Li, W., & Yu, S. (2022) · Oncology and Translational Medicine · doi:10.1007/s10330-022-0551-1
Le traitement périopératoire dans le cancer du poumon non à petites cellules a priori résécables
Assié, J., Greiller, L., Cortot, A. B., & Wislez, M. (2023) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(23)00016-2
The role of cellular immunity in the treatment of cancer
Στραβοκεφάλου, Β. (2023) · doi:10.12681/eadd/54076
Nguyen, V. P., Campbell, K. M., Nowicki, T. S., Elumalai, N., Medina, E., Baselga-Carretero, I., DiNome, M. L., Chang, H. R., Oseguera, D. K., Ribas, A., et al. (2023) · doi:10.1158/2767-9764.23791808
Nguyen, V. P., Campbell, K. M., Nowicki, T. S., Elumalai, N., Medina, E., Baselga-Carretero, I., DiNome, M. L., Chang, H. R., Oseguera, D. K., Ribas, A., et al. (2023) · doi:10.1158/2767-9764.c.6762524.v2
Immunotherapy for Non-small Cell Lung Cancer
Arslan, S., & Gülhan, M. (2023) · Springer eBooks · doi:10.1007/978-3-031-22483-6_69-1
Neoadjuvant Therapy in Locally Advanced Renal Cell Carcinoma
Brown, J. T., Jani, Y. C., Master, V. A., & Bilen, M. A. (2023) · Springer eBooks · doi:10.1007/978-3-031-40901-1_9
Immune Suppression in Surgical Treatment of Solid Tumours: Pathogenesis Links and Correction Methods
Stukan, А. I., Кульбакин, Д. Е., Porkhanov, V. A., Гилевич, И. В., Bodnya, V. N., & Dovlatbekyan, A. A. (2023) · Voprosy Onkologii · doi:10.37469/0507-3758-2023-69-6-986-995
“Это связано с син-тезом IFN-γ и высоким послеоперационным уровнем опухолеспецифичных CD8+Т-ЛФ [54].”
Wang, S., Tian, X., Liu, Z., Li, Y., Deng, X., Tian, W., Zeng, Y., Peng, Y., Xiao, W., & Wu, F. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4702386
Immunotherapy: Neoadjuvant and/or adjuvant? Literature review
Falaleeva, N. A., Bykova, E. A., Grivtsova, L. Y., Белохвостова, А. С., Danilenko, A. A., Сергеевна, П. И., Шегай, П. В., Иванов, С. А., & Каприн, А. Д. (2023) · Practical oncology · doi:10.31917/2404337
Immunotherapy and multimodality therapy for lung cancer
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4429-7
Future Direction of the Development of Immunotherapy for Lung Cancer
Yoshida, T. (2024) · Haigan · doi:10.2482/haigan.64.2
Les cellules lymphocytaires innées dans l’immunosurveillance des tumeurs métastatiques
Rethacker, L. (2021) · theses.fr (ABES) · doi:10.70675/f6fd9463z4034z4eeaza8fazdddec7bd4cb6
Ospina, A. V., Calvo, V., & Provencio, M. (2024) · Revista Colombiana de Hematología y Oncología · doi:10.51643/22562915.516
Martín Vidal, C., & Samtani, S. (2024) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2024.03.005 · Cited by 1
“Esto se debería tanto a la cantidad de linfocitos T como a los niveles de interferón posterior al tratamiento con un anti PD-1, donde se evidencia un aumento en los linfocitos T CD8 dirigidos contra el tumor en sangre y tejidos, capaces de producir interferón gamma y factor de necrosis tumoral 28 .”
Seconds cancers après traitement curatif d'un cancer broncho-pulmonaire
Eberst, G. (2023) · theses.fr (ABES) · doi:10.70675/eb83c1f2zd722z4db9za142z8573c3380462
Rationale for Immunotherapy for Breast Cancer
Karn, T. (2024) · Cancer immunotherapy · doi:10.1007/13905_2024_37
Approaches to the treatment of oligometastatic melanoma in the era of immunotargeted therapy
Ledin, E. V., & Stolyarov, V. I. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-236
Angerilli, V., Rojas, J. J. A., & Fassan, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13376-3.00012-5
Dheer, A., Tortorello, G. N., Shafique, N., Farooq, M. S., Mitchell, T. C., Xu, X., Miura, J. T., & Karakousis, G. C. (2024) · Journal of Surgical Oncology · doi:10.1002/jso.27933
Eberst, G., Westeel, V., Wislez, M., & Slomka, J. (2024) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(24)00086-7
Le, U., Ohm, B., & Schmid, S. (2024) · TumorDiagnostik & Therapie · doi:10.1055/a-2420-1119
“Darüber hinaus wiesen die Versuchstiere bei neoadjuvanter Therapie persistierend höhere Zahlen tumorspezifischer CD8+-T- Lymphozyten im peripheren Blut auf [4].”
Surgical Textbook Outcomes in the Era of Neoadjuvant Systemic Treatment for Skin Cancers
Błoński, P. J., Rutkowski, P. L., Ostaszewski, K., Krotewicz, M., & Czarnecka, A. M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226922
Nakayama, I., Nakamura, Y., & Shitara, K. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.11.004
Curative immunotherapy-based strategies for non-metastatic non-small cell lung cancer
Kuhlman, J. J., Li, S., Manochakian, R., Lou, Y., & Zhao, Y. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00281
He, G., Yang, K., Gao, Z., Zhang, X., & Han, A. (2024) · International Medical Case Reports Journal · doi:10.2147/imcrj.s491862
Lim, B. J. W., Liu, M., Wang, L., Kong, S. L. Y., Yin, T., Yan, C., Xiang, K., Cao, C., Wu, H., Mihai, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.29.635356
Effiom, D. N., & Cohen, S. (2025) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2025.01.005
Research trends of neoadjuvant therapy in lung cancer: a bibliometric analysis
Geng, X., Jiang, Y., Zeng, Y., Cao, W., Lu, Y., Liang, Y., Gu, J. J., & Wang, B. (2025) · Discover Oncology · doi:10.1007/s12672-025-02011-6
“When the primary tumor exists, the neoantigen burden is high and the heterogeneity is limited, allowing the body to generate a broad T-cell response and expand tumor-specific T cells after ICIs application [39–41].”
Othus, M. K. D., Sharon, E., Wu, M. C., Sondak, V. K., Ribas, A., & Patel, S. P. (2025) · Clinical Trials · doi:10.1177/17407745251321371
Amr, N. M. A., Salem, M. L., Shoshan, M. M., & Abouzaid, B. H. (2025) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2025.106252
Immunotherapy in Early Triple-Negative Breast Cancer
Loibl, S., & Hirmas, N. (2025) · Cancer immunotherapy · doi:10.1007/13905_2025_49 · Cited by 1
Zhu, W., Zhang, X., Hu, X., Zhu, K., Zhu, H., Guan, S., Jin, H., Li, Y., Wang, X., Dong, Y., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6365771/v1
Neoadjuvante Therapie des Melanoms
Mengoni, M., Gaffal, E., & Braun, A. D. (2025) · Die Dermatologie · doi:10.1007/s00105-025-05507-y
Zeng, J., Yi, B., Chang, R., Li, J.-S., Yu, Z., Liu, K.-F., & Gao, Y. (2025) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2025.07.166
Peritoneal Immunosurgery: Immunotherapy Augmented Surgery for the Treatment of Peritoneal Cancers
Ozcan, A. I., Aquino‐López, A., McKenna, M. K., Brenner, M. K., & Thompson, A. M. (2025) · Journal of Surgical Oncology · doi:10.1002/jso.70075
“These studies highlight the potential long ‐ term benefits of simple immunomodulatory strategies when employed pre ‐ operatively [292].”
Kalantzakos, T. J., Zhou, Y., Liu, X., Proehl, J., Durfee, C. C., Tamayo, I. M., Temiz, N. A., Troness, B., Soni, A., Gupta, H. B., et al. (2026) · Journal of Clinical and Translational Science · doi:10.1017/cts.2026.10517
Slomka, J., Eberst, G., Westeel, V., & Wislez, M. (2025) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(25)00066-7
From Incision to Immunity: Integrating Surgery and Immunotherapy in Non-Small Cell Lung Cancer
Janes, M. A., Schmidt, A. A., Krieg, G. A., Chouhan, A., Wakefield, M. R., & Fang, Y. (2025) · Immuno · doi:10.3390/immuno5040048
“In a mouse study on breast cancer, it was determined that neoadjuvant therapy 3 days before surgery was significantly more effective in eradicating metastasis post resection than adjuvant therapy [86].”
Menon, N. N. (2025) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2025.08.022
Ladwa, R., McLean, L. S., McGrath, M. E., & Liu, J. (2025) · EJC Skin Cancer · doi:10.1016/j.ejcskn.2025.100767
Self-citationKapur, P., Christie, A. L., Jarmale, V. N., Tahmasebi, F., Xie, B., Miyata, J., Rakheja, D., Cadeddu, J. A., Margulis, V., Hammers, H. J., et al. (2026) · Modern Pathology · doi:10.1016/j.modpat.2026.101069
Gu, C., Teng, X., Sun, X., Liu, J., Zhu, Z., Zhang, L., Wu, Z., Zou, R., Pang, J., & Lyu, X. (2024) · Figshare · doi:10.6084/m9.figshare.25815604
Self-citationGu, C., Teng, X., sun, X., Liu, J., Zhu, Z., Zhang, L., Wu, Z., Zou, R., Pang, J., & Lyu, X. (2024) · Figshare · doi:10.6084/m9.figshare.25815135
Self-citationTanaka, F., Watanabe, Y., Sugawara, S., Okami, J., Muto, S., Okada, M., Horio, Y., Tsuboi, M., Sato, Y., Takamochi, K., et al. (2025) · Cancer Science · doi:10.1111/cas.70300
Villarreal-Otalvaro, C., Luna, F., Espinoza, R. A. R., Lombardini, E., Paxton, Z., Vidali, L., & Coburn, J. M. (2026) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5c01503
Rectal MSI-H/dMMR: neoadjuvant immunotherapy and RT-free strategies
Cabezón‐Gutiérrez, L., Custodio‐Cabello, S., Palka-Kotlowska, M., Chacón-Ovejero, B., & Pacheco-Barcía, V. (2026) · Revisiones en cáncer · doi:10.20960/revcancer.00124
Іmmunotherapy in perioperative treatment of oncological patients. Part ІI
Сорочан, П. П., Prokhach, N. E., Hromakova, I. S., Olkhovskyi, D. V., & Hromakova, I. А. (2025) · Український радіологічний та онкологічний журнал · doi:10.46879/ukroj.4.2025.498-508
Bhat, E. A., Sajjad, S., Sajjad, N., & Ali, T. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-23908-3.00012-5
Advances in Immunotherapy for Breast Cancer
Poland, S. G., Andrade, M. D. O., & Nanda, R. (2026) · ONCOLOGY · doi:10.46883/2026.25921061
Neoadjuvant systemic immunotherapy for skin cancers
Dessinioti, C., & Stratigos, A. (2026) · Cancer · doi:10.1002/cncr.70354
“21 Conversely, tumor removal decreases antigen availability, which potentially limits postresection T - cell activation.”
Imaging of Neoplastic Disease of the Lung
Pinna, A., Saba, L., Polverosi, R., Muzzio, P. C., Vincenzi, M., & Rigoni, B. (2026) · Medical radiology · doi:10.1007/174_2026_686
Recent Advances in Combined Medical and Surgical Therapy for Resectable NSCLC
Balasubramanian, A., Geng, J., Williams, C., Rangamuwa, K., & John, T. (2026) · Respirology · doi:10.1002/resp.70238
“…immunocompetent murine models of breast cancer with sponta-neous metastatic potential: when immunotherapy—including an anti- PD-1 ICI—was administered before surgical removal of the primary tumour, survival was significantly prolonged compared with treatment given only after tumour resection [34].”
Izquierdo-Chamarro, M., Ospina, A. V., & Provencio-Pulla, M. (2026) · Translational Lung Cancer Research · doi:10.21037/tlcr-2025-1-1352
Interest of adjuvant and neoadjuvant vaccination in the early stages of cancer
Damon, M., Clairet, A., Eberst, G., & Adotévi, O. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105290
Liu, J., Lu, H., Zheng, X., Shen, F., & Guo, W. (2026) · Journal of Thoracic Disease · doi:10.21037/jtd-2026-1-0143
“From a biological perspective, neoadjuvant immunotherapy relies on the presence of a macroscopic tumor to serve as an antigen source for expanding tumor-specific T cells (38,39).”
Self-citationImmunotherapy in resectable non–small cell lung cancer; emerging clinical questions
Mitsudomi, T., Sato, K., Suda, K., & Tomizawa, K. (2026) · International Journal of Lung Cancer · doi:10.1016/j.ijlcan.2026.100024 · Cited by 2
Jacoberger-Foissac, C. (2018) · theses.fr (ABES) · doi:10.70675/6f6b5670zeecbz4ac9z8760z516f6d526862 · Cited by 1
Morel, V. (2021) · theses.fr (ABES) · doi:10.70675/31e506dazce13z4d4cz8c40z9823077c170b
Characterization of regulatory T cells populations in breast cancers
Fattori, S. (2023) · theses.fr (ABES) · doi:10.70675/1c177425zb8daz422fza46dz677464719c36
Role of netrin-1 in squamous cell carcinomas
Muñoz-Unceta, N. (2025) · theses.fr (ABES) · doi:10.70675/7f1b9ee6zd478z4391z9e49zdc78589686d9
Xie, H., Liao, Y., Liang, T., Huang, H., Wei, Y., Yang, K., Qin, C., Chen, M., Song, J., Zhou, X., et al. (2026) · BMC Surgery · doi:10.1186/s12893-026-03752-z
“…benefit in the narrow-margin setting may include: the reduction or eradication of micrometastases within the liver parenchyma and circulation by neoadjuvant or conversion therapeutic agents [33]; and the induction and maintenance of an enhanced peripheral tumor-specific immune response [34].”
Cui, Y., Xu, J., Wen, J., Peng, J., Ren, J., Liu, A., Meng, X., Huang, Z., & Liu, A. (2026) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2025.0589
“…relies on pre-operative antigens, an intact lymphatic system, and patient characteristics, such as PD-L1 expression levels, 15 to enhance the activation of the anti-tumor immune response 11 , expand the tumor-specific T-cell population 10,16 , and reduce the risk of disease recurrence.”
Luo, X., Fan, P., Lin, X., Li, Y., & Ding, Z. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1785745
Wen, J., Wang, Q.-X., Yu, X., Liu, Y., Yin, X., Li, S., Zhao, H., Huang, Z., Chen, Y. Q., & Meng, X. (2026) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2025.0800
Optimal Neoadjuvant Approach for Resectable Esophageal Cancer in the Era of Immunotherapy
Lin, G., Ge, F., Liu, Y., Men, Y., & Hui, Z. (2026) · International Journal of Cancer · doi:10.1002/ijc.70521
Ishiwata, T. (2026) · Cancers · doi:10.3390/cancers18111792
“Once the tumor and regional lymph nodes are surgically https://doi.org/10.3390/cancers18111792 removed, the primary sites of immune activation are lost [62], thereby bypassing the opportunity for neoadjuvant treatment.”
InfluentialZhao, A., Chen, W., Yu, L., Cao, X., Wu, B., Zhou, Y., Zhang, W., Zhao, M., Hou, Q., Yao, N. N., et al. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101275
Effects of surgery on cancer metastasis: biological mechanisms and perioperative implications
Nalisa, M., Luvhengo, T. E., & Kapewangolo, P. T. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1796434
Garitaonaindía, Y., Witteveen, S. J., Dionisio, E., Weiss, A. M., Ellebæk, E., Rolfo, C. D., Provencio, M., Blank, C., & Donia, M. (2026) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djag197 · Cited by 1
Shannon, N. B., & Ashford, B. (2026) · Head & Neck · doi:10.1002/hed.70368
“Preclinical data suggest that the neoadjuvant component specifically is superior to adjuvant strategies for eradicating metastatic disease in oral cancer [27], and breast cancer [28] murine models.”
Immune Checkpoint Inhibitors in Early-stage Non-small Cell Lung Cancer: New Standard of Care?
Martín Vidal, C., & Samtani, S. (2024) · Advances in Medicine and Engineering Interdisciplinary Research · doi:10.32629/ameir.v2i3.2458
Evolving Landscape of Immunotherapy in Melanoma
Darwin, A. H., Dickerson, J. C., & Funchain, P. (2026) · JCO Oncology Practice · doi:10.1200/op-25-01301
Жилинский, Н. С., & Ревтович, М. Ю. (2026) · Евразийский онкологический журнал · doi:10.34883/pi.2026.14.2.008
Wang, L., Liu, Y., Zhao, W., Xing, L., Hui, Z., Liu, X., Chen, M., Wu, Y., Chen, L., Zhou, C., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218719
Self-citationScala, A., Mastrantoni, L., Vita, E., Stefani, A., Vitale, A., Polidori, S., Cosmai, A., Ranieri, C., D'Auria, F., Poli, I., et al. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.7071825
Ryan, É. J., O’Reilly, M., Rogers, E. L., MacDermott, R., Cotter, M., Keane, F., McDermott, R., Martin, S., Sheahan, K. D., & Winter, D. (2026) · Lymphatics · doi:10.3390/lymphatics4030036
“Preclinical models demonstrate stronger systemic CD8 + T-cell responses and more effective micrometastatic eradication when checkpoint blockade is administered prior to tumour resection [34].”
Kakimi, K., Kobayashi, Y., & Nagaoka, K. (2026) · Immuno · doi:10.3390/immuno6030047
“In preclinical models, immunotherapy before tumor removal showed superior control of distant disease compared with the same treatment given after surgery, suggesting that the presence of the tumor during treatment can be immunologically useful rather than merely detrimental [30].”
Early-Stage NSCLC: Novel Surgical Techniques and Neoadjuvant, Adjuvant, and Perioperative Therapies
Kim, S. Y., & Woodard, G. A. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000835
Metadata
- Authors
- Liu, J., Blake, S. J., Yong, M. C. R., Harjunpää, H., Ngiow, S. F., Takeda, K., Young, A., O'Donnell, J. S., Allen, S., Smyth, M. J., & Teng, M. W. L.
- Affiliations
- The University of Queensland (AU)
- QIMR Berghofer Medical Research Institute (AU)
- Juntendo University (JP)
- 1Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
- Corresponding author
- Teng, Michele W.L.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2016-12-01
- Volume
- 6
- Issue
- 12
- Pages
- 1382-1399
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2521503673
- Cited by
- 894
- References
- 55
- Citations by year
- 2026: 86 · 2025: 91 · 2024: 135 · 2023: 112 · 2022: 113 · 2021: 112 · 2020: 101 · 2019: 65 · 2018: 50 · 2017: 23 · 2016: 1
- FWCI
- 24.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (15K14410)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- neoadjuvant immunotherapy, adjuvant immunotherapy, metastatic breast cancer, primary tumor resection, tumor-specific immunity, CD8+ T cells, predictive biomarkers
- MeSH terms
- Animals, Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Immunotherapy, Neoplasm Metastasis, Treatment Outcome, Chemotherapy, Adjuvant, CD8-Positive T-Lymphocytes, Neoadjuvant Therapy, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.